{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:36:16Z","timestamp":1757777776445},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Japan Society"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.bbrc.2014.03.146","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T18:01:07Z","timestamp":1396720867000},"page":"311-314","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson\u2019s disease model"],"prefix":"10.1016","volume":"447","author":[{"given":"Masanori","family":"Itakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kohda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeya","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Semi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasu-Taka","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemitsu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Kozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2014.03.146_b0005","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","article-title":"Long-distance retrograde effects of botulinum neurotoxin A","volume":"28","author":"Antonucci","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2014.03.146_b0010","first-page":"124","article-title":"Intracerebrally applied botulinum neurotoxin in experimental neuroscience","volume":"14","author":"Hawlitschka","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bbrc.2014.03.146_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1756287213510962","article-title":"Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice","volume":"6","author":"Knuepfer","year":"2014","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.bbrc.2014.03.146_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxicon.2013.01.017","article-title":"Botulinum neurotoxins","volume":"67","author":"Rossetto","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.bbrc.2014.03.146_b0025","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbrc.2014.03.146_b0030","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bbrc.2014.03.146_b0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmb.2006.07.040","article-title":"A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1\u2013A4","volume":"362","author":"Arndt","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbrc.2014.03.146_b0040","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/bi801686b","article-title":"Catalytic properties of botulinum neurotoxin subtypes A3 and A4","volume":"48","author":"Henkel","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2014.03.146_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn1632","article-title":"Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models","volume":"9","author":"Day","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"Suppl 3","key":"10.1016\/j.bbrc.2014.03.146_b0050","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson\u2019s disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbrc.2014.03.146_b0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.nbd.2010.09.017","article-title":"Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson\u2019s disease","volume":"41","author":"Wree","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrc.2014.03.146_b0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/jnr.23210","article-title":"Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson\u2019s disease","volume":"91","author":"Antipova","year":"2013","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbrc.2014.03.146_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2012.06.008","article-title":"Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats","volume":"234","author":"Holzmann","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbrc.2014.03.146_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.toxicon.2013.07.027","article-title":"Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy","volume":"74","author":"Kato","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.bbrc.2014.03.146_b0075","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/IAI.10.4.750-756.1974","article-title":"Purification and some properties of progenitor toxins of Clostridium botulinum type B","volume":"10","author":"Kozaki","year":"1974","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bbrc.2014.03.146_b0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/IAI.12.6.1262-1270.1975","article-title":"Molecular construction of Clostridium botulinum type A toxins","volume":"12","author":"Sugii","year":"1975","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bbrc.2014.03.146_b0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0168-0102(00)00097-3","article-title":"The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages","volume":"36","author":"Aoi","year":"2000","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bbrc.2014.03.146_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-0270(85)90026-3","article-title":"Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight","volume":"13","author":"Paxinos","year":"1985","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.bbrc.2014.03.146_b0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1254\/jphs.11121FP","article-title":"Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats","volume":"117","author":"Torii","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2014.03.146_b0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.toxicon.2010.10.009","article-title":"Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test","volume":"57","author":"Torii","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.bbrc.2014.03.146_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.febslet.2010.11.045","article-title":"Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1","volume":"585","author":"Pier","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2014.03.146_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.toxicon.2013.11.006","article-title":"Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies","volume":"77","author":"Torii","year":"2014","journal-title":"Toxicon"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14006068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X14006068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T10:02:52Z","timestamp":1597658572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X14006068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0006291X14006068"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.03.146","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson\u2019s disease model","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.03.146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}